Direct thrombin inhibitor

Jump to: navigation, search

WikiDoc Resources for Direct thrombin inhibitor

Articles

Most recent articles on Direct thrombin inhibitor

Most cited articles on Direct thrombin inhibitor

Review articles on Direct thrombin inhibitor

Articles on Direct thrombin inhibitor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Direct thrombin inhibitor

Images of Direct thrombin inhibitor

Photos of Direct thrombin inhibitor

Podcasts & MP3s on Direct thrombin inhibitor

Videos on Direct thrombin inhibitor

Evidence Based Medicine

Cochrane Collaboration on Direct thrombin inhibitor

Bandolier on Direct thrombin inhibitor

TRIP on Direct thrombin inhibitor

Clinical Trials

Ongoing Trials on Direct thrombin inhibitor at Clinical Trials.gov

Trial results on Direct thrombin inhibitor

Clinical Trials on Direct thrombin inhibitor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Direct thrombin inhibitor

NICE Guidance on Direct thrombin inhibitor

NHS PRODIGY Guidance

FDA on Direct thrombin inhibitor

CDC on Direct thrombin inhibitor

Books

Books on Direct thrombin inhibitor

News

Direct thrombin inhibitor in the news

Be alerted to news on Direct thrombin inhibitor

News trends on Direct thrombin inhibitor

Commentary

Blogs on Direct thrombin inhibitor

Definitions

Definitions of Direct thrombin inhibitor

Patient Resources / Community

Patient resources on Direct thrombin inhibitor

Discussion groups on Direct thrombin inhibitor

Patient Handouts on Direct thrombin inhibitor

Directions to Hospitals Treating Direct thrombin inhibitor

Risk calculators and risk factors for Direct thrombin inhibitor

Healthcare Provider Resources

Symptoms of Direct thrombin inhibitor

Causes & Risk Factors for Direct thrombin inhibitor

Diagnostic studies for Direct thrombin inhibitor

Treatment of Direct thrombin inhibitor

Continuing Medical Education (CME)

CME Programs on Direct thrombin inhibitor

International

Direct thrombin inhibitor en Espanol

Direct thrombin inhibitor en Francais

Business

Direct thrombin inhibitor in the Marketplace

Patents on Direct thrombin inhibitor

Experimental / Informatics

List of terms related to Direct thrombin inhibitor

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and Keywords: DTI

Overview

Direct thrombin inhibitors (DTIs) are a class of medication that act as anticoagulants (delaying blood clotting) by directly inhibiting the enzyme thrombin. Some are in clinical use, while others are undergoing clinical development. Several members of the class are expected to replace heparin (and derivatives) and warfarin in various clinical scenarios.

Types

There are two types of DTIs, dependent on their interaction with the thrombin molecule. Bivalent DTIs (hirudin and analogs) bind both to the active site and exosite 1, while univalent DTIs bind only to the active site.[1]

Bivalent

Hirudin and derivatives were originally discovered in Hirudo medicinalis:

Univalent

Univalent DTIs include:

Uses

Bivalent DTIs enjoy limited use in circumstances where heparin would be indicated but cannot be used, such as the acute coronary syndrome ("unstable angina"). As they are administered by injection (intravenous, intramuscular or subcutaneous), they are less suitable for long-term treatment.[1]

Argatroban (as well as the hirudins) are used for heparin-induced thrombocytopenia, a rare but serious complication of heparin treatment that requires anticoagulation (as it increases both arterial and venous thrombosis risk) but not with the putative agent, heparin.[1]

Ximelagatran showed good efficacy compared with warfarin in several trials in prevention and treatment of deep vein thrombosis and as thromboprophylaxis in atrial fibrillation.[1] Development was stopped by manufacturer AstraZeneca, however, because of reports of liver enzyme derangements and liver failure.[2] Dabigatran is under development for similar indications.

Monitoring

There is no therapeutic drug monitoring widely available for DTIs, in contrast with warfarin (INR) and heparin (APTT). The ecarin clotting time, although not in general clinical use, would be the most appropriate monitoring test.[1]

Reversal

Idarucizumab (Praxbind) can reverse the effects of dabigatran.[3]

Reference

  1. 1.0 1.1 1.2 1.3 1.4 Di Nisio M, Middeldorp S, Büller H (2005). "Direct thrombin inhibitors". N Engl J Med. 353 (10): 1028–40. PMID 16148288.
  2. "AstraZeneca Decides to Withdraw Exanta" (Press release). AstraZeneca. February 14, 2006.
  3. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA; et al. (2015). "Idarucizumab for Dabigatran Reversal". N Engl J Med. 373 (6): 511–20. doi:10.1056/NEJMoa1502000. PMID 26095746.



Linked-in.jpg